RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
Phase II study shows RAD51-foci score predicts olaparib response in BRCA1/2, PALB2, RAD51C/D mutated breast cancer. Study enrolled 65 patients.
Researchers studied how well a drug called olaparib works for patients with advanced breast cancer. They focused on specific gene changes to see if they could predict who would benefit most from the t…
Phase 1/2 Study of Dual-Target CAR-NK Cells in Recurrent Ovarian Cancer
This Phase 1/2 trial assesses the safety and preliminary efficacy of dual-target CAR-NK cells in recurrent ovarian cancer, focusing on dose-limiting toxicities and treatment-emergent adverse events.
Researchers are testing a new treatment using special immune cells to fight recurrent ovarian cancer. They are looking at how safe this treatment is and if it can help shrink tumors.…
Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes
This Phase 2/3 trial examines the relationship between ER and UGT SNPs and Raloxifene's efficacy and side effects in 600 BC-LCIS patients. Results pending.
This study looks at how certain genes might affect the effectiveness and side effects of Raloxifene in breast cancer patients. Researchers are trying to find connections between these genes and how we…